2seventy bio (TSVT) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

TSVT 2seventy bio

Watchlist

3.140
+0.220+7.53%

Close Dec 20 16:00 ET

3.140
0.0000.00%

Post 20:05 ET

161.99MMarket Cap-1.72P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

2seventy Bio: Buy Rating Amidst Challenges and Growth Potential in BCMA CAR-T Therapy
TipRanksDec 6 00:58 ET · Ratings
2seventy Bio (TSVT) Gets a Hold From Morgan Stanley
TipRanksDec 5 10:20 ET · Ratings
Insider Sale: Director at $TSVT (TSVT) Sells 3,900 Shares
Quiver QuantitativeNov 20 16:20 ET
US$8.25: That's What Analysts Think 2seventy Bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest Results
Yahoo FinanceNov 15 08:58 ET
When Will 2seventy Bio, Inc. (NASDAQ:TSVT) Become Profitable?
Simply Wall StNov 15 07:25 ET
2seventy Bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Yahoo FinanceNov 14 08:46 ET

Comments

Jaguar8

Sep 25 06:33

NEWS

$2seventy bio (TSVT.US)$
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
2seventy bio and Bristol Myers Squibbhave decided to discontinue enrollment in the Phase 3 KarMMa-9 studyevaluating Abecma in newly diagnosed multiple myeloma patients. This decision is expected to result in over $80 million in cost savings for 2seventy bio and accelerate their path to breakeven in 2025.
The company reports positive momentum for Abecma, wi...

Stock_Drift

Sep 25 05:08

$2seventy bio (TSVT.US)$

Trytosaveabit

Apr 25 06:11

$2seventy bio (TSVT.US)$ 2Seventy Bio Inc: Abecma (Idecabtagene Vicleucel, or Ide-Cel) Generated Approximately $52 Mln in U.S. Revenue During Q1 of 2024

Meltyy

Apr 9 10:48

FDA PDUFA Update…

🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals (SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech (LEGN.US)$ & $Johnson & Johnson (JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca (AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio (TSVT.US)$ & $Bristol-Myers Squibb (BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals (VNDA.US)$...